Amgen's Tezspire Wins Big in Eosinophilic Esophagitis Phase III Trial

Amgen and AstraZeneca have announced positive Phase III results for Tezspire in treating eosinophilic esophagitis, paving the way for a potential label expansion.

The data will support regulatory submissions to make Tezspire a treatment option in this condition.

A successful label expansion could open up a broader market opportunity and put Tezspire directly into competition with an established therapy for eosinophilic esophagitis.

Amgen is a large US biotech company with a significant presence in the healthcare industry, focusing on discovering, developing, manufacturing, and delivering human therapeutics worldwide.